Abstract
Ulcerative colitis is a chronic, idiopathic, inflammatory disease of the colon and rectum that may be associated with growth failure, nutritional derangements and psychosocial ramifications in affected children. Multiple medical options are available to achieve disease remission; however, some of these medications can have unwanted side effects, especially in younger patients. With increased understanding of the etiology of the disease, newer therapeutic alternatives have arisen in the form of biologic therapies, namely monoclonal antibodies targeted to a specific protein or receptor. Specifically, infliximab, an anti-TNF-α agent, has been shown to be safe and effective for the treatment of moderate-to-severe pediatric ulcerative colitis.
Original language | English (US) |
---|---|
Pages (from-to) | 659-665 |
Number of pages | 7 |
Journal | Expert Review of Gastroenterology and Hepatology |
Volume | 6 |
Issue number | 6 |
DOIs | |
State | Published - Dec 2012 |
Keywords
- anti-TNF-α agents
- inflammatory bowel disease
- infliximab
- ulcerative colitis
ASJC Scopus subject areas
- Hepatology
- Gastroenterology